Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose.

Hisashi Shiga Yoichi KakutaKumiko AnYuko AbeShinichi FujimakiYusuke ShimoyamaTakeo NaitoRintaro MoroiMasatake KurohaSeik-Soon KhorYosuke KawaiKatsushi TokunagaYoshitaka KinouchiAtsushi Masamune

Published in: Journal of gastroenterology and hepatology (2022)

Our findings further support the recommendation for COVID-19 vaccination in patients under immunosuppressive therapy, especially additional third dose for patients receiving anti-TNF agents and/or thiopurine or tofacitinib.

Keyphrases

coronavirus disease
sars cov
patients with inflammatory bowel disease
rheumatoid arthritis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
mesenchymal stem cells
ulcerative colitis